Sterenn Davis

Sterenn has expertise in molecular biology and next generation sequencing, and is excited to explore how the application of innovations in these fields can revolutionise the drug discovery process and pipeline. Sterenn has over eight years of experience in therapeutics discovery.

Prior to joining Theolytics, she created and established a bespoke single-cell next generation sequencing pipeline at Immunocore.

Furthermore, while at the UCL Institute of Ophthalmology she contributed to the discovery of a new therapeutic monoclonal antibody.

Sterenn has a PhD in Physics from the University of Exeter.